Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: A multicenter study
| Autor: | Michael A. Choti, Thierry J. Debaere, Athour Gevargez, Rodolfo Capanna, Gilbert Y. Wong, Michael A. Farrell, J. William Charboneau, Matthew P. Goetz, Matthew R. Callstrom, Joseph Rubin, Mark B. Saker, Timothy J. Welch, Daniele Regge, Paul J. Novotny, Kamran Ahrar, Ivy A. Petersen, Dietrich Grönemeyer, Jeff A. Sloan, Robert A. Beres, Timothy P. Mans |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Percutaneous Radiofrequency ablation Pain Bone Neoplasms Osteolysis Metastasis law.invention Refractory law medicine Clinical endpoint Humans In patient Ultrasonography Interventional Aged Aged 80 and over business.industry Middle Aged medicine.disease Surgery Treatment Outcome Oncology Multicenter study Fluoroscopy Catheter Ablation Female Cementoplasty business Tomography X-Ray Computed |
| Popis: | Purpose Few options are available for pain relief in patients with bone metastases who fail standard treatments. We sought to determine the benefit of radiofrequency ablation (RFA) in providing pain relief for patients with refractory pain secondary to metastases involving bone. Patients and Methods Thirty-one US and 12 European patients with painful osteolytic metastases involving bone were treated with image-guided RFA using a multitip needle. Treated patients had ≥ 4/10 pain and had either failed or were poor candidates for standard treatments such as radiation or opioid analgesics. Using the Brief Pain Inventory–Short Form, worst pain intensity was the primary end point, with a 2-unit drop considered clinically significant. Results Forty-three patients were treated (median follow-up, 16 weeks). Before RFA, the mean score for worst pain was 7.9 (range, 4/10 to 10/10). Four, 12, and 24 weeks following treatment, worst pain decreased to 4.5 (P < .0001), 3.0 (P < .0001), and 1.4 (P = .0005), respectively. Ninety-five percent (41 of 43 patients) experienced a decrease in pain that was considered clinically significant. Opioid usage significantly decreased at weeks 8 and 12. Adverse events were seen in 3 patients and included (1) a second-degree skin burn at the grounding pad site, (2) transient bowel and bladder incontinence following treatment of a metastasis involving the sacrum, and (3) a fracture of the acetabulum following RFA of an acetabular lesion. Conclusion RFA of painful osteolytic metastases provides significant pain relief for cancer patients who have failed standard treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|